₁Anne-Marie Batt

Key Opinion Leader In [Anne-Marie Batt is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

no keywords assigned

Keywords (9) [keywords assigned to Anne-Marie Batt articles by PubMed, the leading number and the color conveys importance]

₁Humans | ₁Pharmacogenetics | ₁Cytochrome P-450 Enzyme System | ₁Lipid Metabolism | ₁Cardiovascular System | ₁Cardiovascular Agents | ₁Genotype | ₁Polymorphism, Genetic | ₁Mutation

Other [context-specific ads]

Anne-Marie Batt Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Anne-Marie Batt might be a good expert witness on these terms]

₇drugs | ₆cardiovascular | ₃metabolism | ₃variability | ₃drug | ₃phase | ₂effects | ₂pharmacogenomics | ₂risk | ₂transporters | ₂affecting | ₂response | ₂among | ₂system | ₂adverse | ₂proteins | ₂enzymes | ₂polymorphisms | ₂human | ₂targets | ₁variation | ₁impaired | ₁approach | ₁biochemical | ₁identified | ₁genetic | ₁moved | ₁best | ₁genetics | ₁emphasizing | ₁cyp | ₁variations
₃cardiovascular drugs | ₂adverse effects | ₂pharmacogenomics drugs | ₂affecting cardiovascular | ₂cardiovascular system | ₂drugs affecting | ₁p450 cyp | ₁linked cardiovascular | ₁possible consequences | ₁targets proteins | ₁variation receptors | ₁pharmacogenomics | ₁considered polymorphisms | ₁risk | ₁personalized genotype-dependent | ₁system variability | ₁efficacy adverse | ₁phase enzymes | ₁phase ii | ₁partly genetics | ₁various polymorphic | ₁metabolism drugs | ₁mainly indicated | ₁drugs cyp3a4 | ₁indicated best | ₁best known | ₁originates partly | ₁drugs biotransformation | ₁relevant metabolism | ₁glutathion-s-transferase gsh-t | ₁drug metabolism | ₁including cytochromes
₂pharmacogenomics drugs affecting | ₂drugs affecting cardiovascular | ₂affecting cardiovascular system | ₁moved approach personalized | ₁cyp3a4 cyp2c9 cyp2c19 | ₁system among relevant | ₁risk concept emphasizing | ₁human genome together | ₁pharmacogenomics | ₁angiotensin-converting enzyme beta-adrenergic | ₁phase enzymes including | ₁risk | ₁cyp2c9 cyp2c19 cyp2d6 | ₁system variability drug | ₁must considered polymorphisms | ₁revealed sources human | ₁identified involved interindividual | ₁family must considered | ₁emphasizing impaired metabolism | ₁targets proteins identified | ₁transporters among pharmacological | ₁various polymorphic phase | ₁simultaneous progress knowledge | ₁polymorphic phase enzymes | ₁partly genetics possible | ₁linked cardiovascular risk | ₁source variability variability | ₁cardiovascular drugs cyp3a4 | ₁limited regard cardiovascular | ₁pharmacological targets proteins | ₁metabolized various polymorphic | ₁interindividual variations response

Authoratory™
•home •community •tutorial •authors •keywords •search •top ranked •login	Update 2008, Q3 Live! Excel CSV XML print ₁Anne-Marie Batt 2003 \| 2004 >> Summary Social Network Interests Funding Articles Comments All Key Opinion Leader In [Anne-Marie Batt is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors] no keywords assigned Keywords (9) [keywords assigned to Anne-Marie Batt articles by PubMed, the leading number and the color conveys importance] ₁Humans \| ₁Pharmacogenetics \| ₁Cytochrome P-450 Enzyme System \| ₁Lipid Metabolism \| ₁Cardiovascular System \| ₁Cardiovascular Agents \| ₁Genotype \| ₁Polymorphism, Genetic \| ₁Mutation Other [context-specific ads] Anne-Marie Batt Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Anne-Marie Batt might be a good expert witness on these terms] ₇drugs \| ₆cardiovascular \| ₃metabolism \| ₃variability \| ₃drug \| ₃phase \| ₂effects \| ₂pharmacogenomics \| ₂risk \| ₂transporters \| ₂affecting \| ₂response \| ₂among \| ₂system \| ₂adverse \| ₂proteins \| ₂enzymes \| ₂polymorphisms \| ₂human \| ₂targets \| ₁variation \| ₁impaired \| ₁approach \| ₁biochemical \| ₁identified \| ₁genetic \| ₁moved \| ₁best \| ₁genetics \| ₁emphasizing \| ₁cyp \| ₁variations ₃cardiovascular drugs \| ₂adverse effects \| ₂pharmacogenomics drugs \| ₂affecting cardiovascular \| ₂cardiovascular system \| ₂drugs affecting \| ₁p450 cyp \| ₁linked cardiovascular \| ₁possible consequences \| ₁targets proteins \| ₁variation receptors \| ₁pharmacogenomics \| ₁considered polymorphisms \| ₁risk \| ₁personalized genotype-dependent \| ₁system variability \| ₁efficacy adverse \| ₁phase enzymes \| ₁phase ii \| ₁partly genetics \| ₁various polymorphic \| ₁metabolism drugs \| ₁mainly indicated \| ₁drugs cyp3a4 \| ₁indicated best \| ₁best known \| ₁originates partly \| ₁drugs biotransformation \| ₁relevant metabolism \| ₁glutathion-s-transferase gsh-t \| ₁drug metabolism \| ₁including cytochromes ₂pharmacogenomics drugs affecting \| ₂drugs affecting cardiovascular \| ₂affecting cardiovascular system \| ₁moved approach personalized \| ₁cyp3a4 cyp2c9 cyp2c19 \| ₁system among relevant \| ₁risk concept emphasizing \| ₁human genome together \| ₁pharmacogenomics \| ₁angiotensin-converting enzyme beta-adrenergic \| ₁phase enzymes including \| ₁risk \| ₁cyp2c9 cyp2c19 cyp2d6 \| ₁system variability drug \| ₁must considered polymorphisms \| ₁revealed sources human \| ₁identified involved interindividual \| ₁family must considered \| ₁emphasizing impaired metabolism \| ₁targets proteins identified \| ₁transporters among pharmacological \| ₁various polymorphic phase \| ₁simultaneous progress knowledge \| ₁polymorphic phase enzymes \| ₁partly genetics possible \| ₁linked cardiovascular risk \| ₁source variability variability \| ₁cardiovascular drugs cyp3a4 \| ₁limited regard cardiovascular \| ₁pharmacological targets proteins \| ₁metabolized various polymorphic \| ₁interindividual variations response

	The content of this page was generated automatically by a computer program. Copyright © 2006-2009 Authoratory.com \| All rights reserved \| Terms of use \| Privacy policy

1Anne-Marie Batt

Key Opinion Leader In [Anne-Marie Batt is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

Keywords (9) [keywords assigned to Anne-Marie Batt articles by PubMed, the leading number and the color conveys importance]

Other [context-specific ads]

Anne-Marie Batt Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Anne-Marie Batt might be a good expert witness on these terms]

₁Anne-Marie Batt